DK2443232T3 - System til heterolog ekspression af et viralt protein i en værtsfimrecelle - Google Patents

System til heterolog ekspression af et viralt protein i en værtsfimrecelle Download PDF

Info

Publication number
DK2443232T3
DK2443232T3 DK10724856.9T DK10724856T DK2443232T3 DK 2443232 T3 DK2443232 T3 DK 2443232T3 DK 10724856 T DK10724856 T DK 10724856T DK 2443232 T3 DK2443232 T3 DK 2443232T3
Authority
DK
Denmark
Prior art keywords
protein
leu
ser
gly
asn
Prior art date
Application number
DK10724856.9T
Other languages
English (en)
Inventor
Marcus Hartmann
Christine Sachse
Jenny Apelt
Ulrike Bockau
Original Assignee
Cilian Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilian Ag filed Critical Cilian Ag
Application granted granted Critical
Publication of DK2443232T3 publication Critical patent/DK2443232T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (10)

  1. SYSTEM TIL HETEROLOG EKSPRESSION AF ET VIRALT PROTEIN I EN VÆRTSFIMRECELLE
    1. System til heterolog ekspression af et viralt overfladeprotein til anvendelse i eller som en vaccine, hvilket system omfatter a) en værtsfimrecelle, b) mindst ét nukleinsyremolekyle, som omfatter en nukleinsyresekvens, der koder for det virale overfladeprotein, og c) en promotor, som er operativt forbundet til nukleinsyremolekylet.
  2. 2. System ifølge krav 1, som endvidere omfatter d) en signalsekvens, som er operativt forbundet til nukleinsyren, hvilken signalsekvens er ansvarlig for secerneringen af det virale overfladeprotein, der kodes for af nukleinsyren, til det ekstracellulære medium.
  3. 3. System ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at den transgene fimrecelle er medlem af Tetrahymenidae-familien.
  4. 4. System ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at det virale overfladeprotein er et viralt fusionsprotein, fortrinsvis mindst ét valgt fra gruppen bestående af viralt fusionsprotein fra Klasse I, Klasse II eller Klasse III.
  5. 5. System ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at det virale overfladeprotein, der kodes for af nukleinsyren, mangler mindst ét hydrofobt domæne eller en del deraf.
  6. 6. Værtsfimrecelle, som er transficeret med en vektor, der omfatter et nukleinsyremolekyle, som koder for et viralt overfladeprotein til anvendelse i eller som en vaccine.
  7. 7. Fremgangsmåde til fremstilling af mindst ét viralt overfladeprotein i en værtsfimrecelle til anvendelse i eller som en vaccine, hvilken fremgangsmåde omfatter trinene a) transfektion af værtsfimrecellen med vektoren ifølge krav 6 og b) dyrkning af værtscellen under betingelser, som muliggør ekspression af et protein.
  8. 8. Fremgangsmåde ifølge krav 7, kendetegnet ved, at den endvidere omfatter et trin til c) dyrkning af værtscellen under betingelser, som muliggør secernering af det udtrykte protein af et protein.
  9. 9. Metode til fremstilling af en farmaceutisk sammensætning, hvilken metode omfatter fremgangsmåden ifølge krav 7.
  10. 10. Farmaceutisk sammensætning, som omfatter et protein, der er fremstillet med en metode ifølge krav 9, hvilken sammensætning er en vaccine.
DK10724856.9T 2009-06-17 2010-06-15 System til heterolog ekspression af et viralt protein i en værtsfimrecelle DK2443232T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0910357A GB2471093A (en) 2009-06-17 2009-06-17 Viral protein expression in ciliates
PCT/EP2010/058360 WO2010146043A2 (en) 2009-06-17 2010-06-15 System for the heterologous expression of a viral protein in a ciliate host cell

Publications (1)

Publication Number Publication Date
DK2443232T3 true DK2443232T3 (da) 2017-05-22

Family

ID=40940892

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10724856.9T DK2443232T3 (da) 2009-06-17 2010-06-15 System til heterolog ekspression af et viralt protein i en værtsfimrecelle

Country Status (11)

Country Link
US (1) US8377682B2 (da)
EP (1) EP2443232B1 (da)
JP (1) JP2012529899A (da)
CN (2) CN107083393B (da)
CA (1) CA2765799C (da)
DK (1) DK2443232T3 (da)
ES (1) ES2627402T3 (da)
GB (1) GB2471093A (da)
IN (1) IN2012DN00448A (da)
PL (1) PL2443232T3 (da)
WO (1) WO2010146043A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471093A (en) 2009-06-17 2010-12-22 Cilian Ag Viral protein expression in ciliates
WO2011100369A2 (en) * 2010-02-09 2011-08-18 The Trustees Of Columbia University In The City Of New York Methods for altering polypeptide expression and solubility
JP6841184B2 (ja) * 2017-08-07 2021-03-10 日立金属株式会社 半導体装置の製造方法
CN108130340B (zh) * 2018-02-06 2021-02-23 福建省农业科学院畜牧兽医研究所 表达鸭源禽流感病毒ns1蛋白的方法以及该方法的应用
CN114569710A (zh) * 2022-03-09 2022-06-03 华南农业大学 一种基于嗜热四膜虫tubulin蛋白的刺激隐核虫疫苗的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752473A (en) 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
WO1994020622A1 (en) * 1993-03-11 1994-09-15 Akzo Nobel N.V. Polypeptide fragment capable of inducing neutralising antibodies against feline immuno-deficiency virus
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU2756100A (en) * 1999-02-04 2000-08-25 Cornell Research Foundation Inc. Diagnostic and protective antigen gene sequences of ichthyophthirius
US20030027192A1 (en) * 2001-07-13 2003-02-06 Gorovsky Martin A. Tetrahymena metallothionein gene promoter and its use
ATE384785T1 (de) * 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
EP1485489A2 (en) * 2002-03-19 2004-12-15 Cilian AG Dna sequences of major secreted proteins from the ciliate tetrahymena and use thereof
DE10214413A1 (de) * 2002-03-30 2003-10-09 Nutrinova Gmbh Expression von rekombinanten humanen Proteinen in Tetrahymena
DE10214406A1 (de) * 2002-03-30 2003-10-09 Nutrinova Gmbh Verfahren und Marker zur einfachen Transformation und Selektion von rekombinanten Protisten
DE602006020140D1 (de) * 2005-07-13 2011-03-31 Cilian Ag Hitzeinduzierbare tetrahymena-promotoren und deren verwendung
US20070042002A1 (en) * 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
CA2696764A1 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
GB2471093A (en) 2009-06-17 2010-12-22 Cilian Ag Viral protein expression in ciliates

Also Published As

Publication number Publication date
CA2765799C (en) 2018-04-03
ES2627402T3 (es) 2017-07-28
EP2443232B1 (en) 2017-03-01
US8377682B2 (en) 2013-02-19
CN107083393A (zh) 2017-08-22
JP2012529899A (ja) 2012-11-29
CN102712909A (zh) 2012-10-03
GB0910357D0 (en) 2009-07-29
US20110008835A1 (en) 2011-01-13
PL2443232T3 (pl) 2017-08-31
CN107083393B (zh) 2021-12-10
WO2010146043A2 (en) 2010-12-23
WO2010146043A3 (en) 2011-02-17
IN2012DN00448A (da) 2015-05-15
CA2765799A1 (en) 2010-12-23
GB2471093A (en) 2010-12-22
EP2443232A2 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
JP7065803B2 (ja) 植物におけるインフルエンザウイルス様粒子の生成
CN111234036B (zh) 非洲猪瘟病毒p72融合蛋白及其制备方法和应用
CN106946995B (zh) Ⅰ群血清4型禽腺病毒基因工程亚单位疫苗、其制备方法及应用
CA2774640C (en) Virus like particles comprising target proteins fused to plant viral coat proteins
KR20100120157A (ko) 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs)
CA2765799C (en) System for the heterologous expression of a viral protein in a ciliate host cell
Liu et al. Recombinant H7 hemagglutinin expressed in glycoengineered Pichia pastoris forms nanoparticles that protect mice from challenge with H7N9 influenza virus
Marcekova et al. Heterologous expression of full-length capsid protein of porcine circovirus 2 in Escherichia coli and its potential use for detection of antibodies
CN110256539A (zh) O型口蹄疫病毒新型基因工程亚单位疫苗
CN113061167B (zh) 兔出血症病毒重组抗原及其应用
CN1860130B (zh) 新的可溶且稳定的三聚体形式的gp41多肽
CN111315408A (zh) 在嗜热毁丝霉(myceliophthora thermophila)中生产流感疫苗
CN112679586A (zh) H5、h7亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN115916804A (zh) 稳定的冠状病毒刺突蛋白融合蛋白
US20220145317A1 (en) Influenza virus-like particle production in plants
López-Tavera et al. Production of Recombinant HA1 subunit from H5N1 Avian Influenza Hemagglutinin in Escherichia coli
AU2021286574A1 (en) Method of making virus-like particle
CA2907591C (en) Influenza virus-like particle production in plants
Esteban et al. Production of Recombinant HA1 subunit from H5N1 Avian Influenza Hemagglutinin in Escherichia coli
WO2004048562A1 (ja) ヒト由来β1,3−N−アセチルグルコサミニルトランスフェラーゼ2の製造方法